|Bid||13.750 x 1400|
|Ask||13.800 x 800|
|Day's Range||13.650 - 14.000|
|52 Week Range||10.500 - 22.750|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.98|
Abeona Therapeutics Inc’s (NASDAQ:ABEO): Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. With the latest financial yearRead More...
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.
Clinical trial for ABO-101 marks the 2nd MPS III program in Europe Company plans to initiate additional clinical sites in European countries including France, Germany and the United Kingdom NEW YORK and ...
Citi's 13th Annual Biotech Conference- September 5-6 th in Boston, MA Jefferies Gene Therapy Summit- September 27 th in New York, NY NEW YORK and CLEVELAND, Sept. 04, 2018-- Abeona Therapeutics Inc., a ...
NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AgroFresh ...
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -56.25% and -54.83%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Dallas-based company said it had a loss of 25 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
NEW YORK and CLEVELAND, Aug. 09, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Max Colao as Chief Commercial Officer. Mr. Colao has more than 20 years of global pharmaceutical and biotechnology experience, having most recently served as the Senior Vice President of US Commercial Operations at Alexion Pharmaceuticals, Inc. The Company also announced Jeffrey B. Davis will be stepping down from his role as Chief Operating Officer at the end of the quarter to ensure a smooth transition. In an ongoing commitment to enhance the capabilities of its senior team, Abeona recently appointed Kristina Maximenko as Global Head of Human Resources.
Abeona Therapeutics (ABEO) needs investors to pay close attention to the stock based on moves in the options market lately.
Stock Research Monitor: RGNX, RGLS, and ABEO LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on XXII sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of stockholders of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (ABEO) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly diminish shareholder value and do not benefit the Company.
Cell and gene therapy development hitting fever pitch globally as more products enter phase 3 and late-stage testing. Growing their sales consistently, and partnered with high-profile public clients, ORGS could be significantly undervalued with continued executiona and expansion. NEW YORK, NY / ACCESSWIRE / June 7, 2018 / The curative potential of gene and cell therapies has kept these new pharmaceutical products front and center for healthcare investors for the last 3 years.
Abeona Therapeutics Inc (NASDAQ: ABEO ), which employs gene and cell therapy for potential rare disease treatments, has a favorable risk-reward profile, according to Seaport Global Securities. The Analyst ...
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).
Stock investors looking for long-term growth plays in the health care space may seek guidance from Fidelity Fund manager Eddie Yoon, who oversees more than $35 billion in assets and leads the firm's health sector with a team of 12 investment professionals.
Today I will take a look at Abeona Therapeutics Inc’s (NASDAQ:ABEO) most recent earnings update (31 March 2018) and compare these latest figures against its performance over the past fewRead More...